



CSOP LEVERAGED AND INVERSE SERIES II

(An umbrella unit trust established in Hong Kong)

UNAUDITED SEMI-ANNUAL REPORT

CSOP NASDAQ-100 INDEX DAILY (2X) LEVERAGED PRODUCT
(Stock Code: 7266)

CSOP GOLD FUTURES DAILY (2X) LEVERAGED PRODUCT
(Stock Code: 7299)

CSOP CSI 300 INDEX DAILY (2X) LEVERAGED PRODUCT
(Stock Code: 7233)

CSOP CSI 300 INDEX DAILY (-1X) INVERSE PRODUCT
(Stock Code: 7333)

CSOP FTSE CHINA A50 INDEX DAILY (2X) LEVERAGED PRODUCT
(Stock Code: 7248)

CSOP FTSE CHINA A50 INDEX DAILY (-1X) INVERSE PRODUCT
(Stock Code: 7348)

CSOP GOLD FUTURES DAILY (-1X) INVERSE PRODUCT
(Stock Code: 7374)

CSOP WTI CRUDE OIL FUTURES DAILY (-1X) INVERSE PRODUCT
(Stock Code: 7345)

FOR THE PERIOD ENDED 30 JUNE 2023

CSOP CSI BROKERAGE INDEX DAILY (2X) LEVERAGED PRODUCT
(Stock Code: 7252)

FOR THE PERIOD FROM 18 OCTOBER 2022 (DATE OF INCEPTION) TO
30 JUNE 2023

(SUB-FUNDS OF CSOP LEVERAGED AND INVERSE SERIES II)

CSOP LEVERAGED AND INVERSE SERIES II

CONTENTS

	Page
Condensed Statement of Financial Position	1 - 4
Condensed Statement of Comprehensive Income	5 - 8
Condensed Statement of Changes in Net Assets Attributable to Unitholders	9 - 11
Condensed Statement of Cash Flows	12 - 20
Condensed Notes to the Financial Statements	21 - 33
Investment Portfolio (Unaudited)	34 - 42
Statement of Movements in Investment Portfolio (Unaudited)	43 - 51
Holdings of Collateral (Unaudited)	52 - 53
Performance Record (Unaudited)	54 - 56
Underlying Index Constituent Stock Disclosure (Unaudited)	57 - 59
Details in Respect of Swap Fees for Financial Derivative Instruments (Unaudited)	60
Management and Administration	61

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF FINANCIAL POSITION

As at 30 June 2023

	CSOP NASDAQ-100 Index Daily (2x) Leveraged Product		CSOP Gold Futures Daily (2x) Leveraged Product		CSOP CSI 300 Index Daily (2x) Leveraged Product		CSOP CSI 300 Index Daily (-1x) Inverse Product	
	30 June 2023 (Unaudited) US\$	31 December 2022 (Audited) US\$	30 June 2023 (Unaudited) US\$	31 December 2022 (Audited) US\$	30 June 2023 (Unaudited) RMB	31 December 2022 (Audited) RMB	30 June 2023 (Unaudited) RMB	31 December 2022 (Audited) RMB
ASSETS								
CURRENT ASSETS								
Financial assets at fair value through profit or loss	2,320,555	1,622,879	32,138,819	56,750,211	36,744,770	32,742,031	3,025,304	297,363
Interest receivable	7	–	1,330	3,858	–	–	–	–
Interest receivable from swap contracts	–	–	–	–	–	–	1,854	–
Other receivables	1,623	2,581	29,622	36,768	40,429	44,172	202,906	15,601
Amounts due from broker	–	–	–	–	–	–	–	806
Margin accounts	3,411,521	3,743,624	46,714,628	37,230,118	92,892,248	92,671,062	8,829,929	10,413,933
Cash and cash equivalents	9,249,618	4,990,020	98,699,463	101,971,880	75,944,169	81,477,647	14,086,917	15,836,306
TOTAL ASSETS	14,983,324	10,359,104	177,583,862	195,992,835	205,621,616	206,934,912	26,146,910	26,564,009
LIABILITIES								
CURRENT LIABILITIES								
Financial liabilities at fair value through profit or loss	–	1,143,284	6,747,291	–	358,758	2,235,587	275,625	93,336
Interest payable from swap contracts	–	–	–	–	340,713	780,590	–	–
Amounts due to participating dealers	–	–	–	–	–	–	–	–
Amounts due to broker	–	–	–	–	–	–	2,206	–
Management fee payable	40,858	21,046	778,352	774,460	916,896	887,043	114,855	293,785
Other payables and accruals	23,952	31,070	117,465	89,285	378,931	544,216	374,583	502,547
Cash collateral liabilities	–	–	–	1,520,000	1,600,000	–	–	–
TOTAL LIABILITIES	64,810	1,195,400	7,643,108	2,383,745	3,595,298	4,447,436	767,269	889,668
EQUITY								
Net assets attributable to unitholders	14,918,514	9,163,704	169,940,754	193,609,090	202,026,318	202,487,476	25,379,641	25,674,341
TOTAL LIABILITIES AND EQUITY	14,983,324	10,359,104	177,583,862	195,992,835	205,621,616	206,934,912	26,146,910	26,564,009
Number of units in issue	7,220,000	8,020,000	177,800,000	212,200,000	49,200,000	45,200,000	4,000,000	4,000,000
Net asset value per unit	2.0663	1.1426	0.9558	0.9124	4.1062	4.4798	6.3449	6.4186

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF FINANCIAL POSITION (continued)

As at 30 June 2023

	CSOP FTSE China A50 Index Daily (2x) Leveraged Product		CSOP FTSE China A50 Index Daily (-1x) Inverse Product		CSOP Gold Futures Daily (-1x) Inverse Product		CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product	
	30 June 2023 (Unaudited) US\$	31 December 2022 (Audited) US\$	30 June 2023 (Unaudited) US\$	31 December 2022 (Audited) US\$	30 June 2023 (Unaudited) US\$	31 December 2022 (Audited) US\$	30 June 2023 (Unaudited) US\$	31 December 2022 (Audited) US\$
ASSETS								
CURRENT ASSETS								
Financial assets at fair value through profit or loss	1,347,875	1,193,673	1,082,267	1,105,314	147,243	436,388	307,728	419,666
Interest receivable	15	–	–	–	–	–	5	–
Interest receivable from swap contracts	–	–	–	–	–	–	–	–
Other receivables	20,816	25,183	9,730	6,465	59,010	35,932	58,619	37,874
Amounts due from broker	–	85,346	15,354	–	321,776	–	–	–
Margin accounts	343,416	311,509	116,819	110,598	65,642	383,945	212,130	516,958
Cash and cash equivalents	1,764,064	1,779,545	1,677,779	1,655,503	868,174	1,485,067	830,829	1,374,622
TOTAL ASSETS	3,476,186	3,395,256	2,901,949	2,877,880	1,461,845	2,341,332	1,409,311	2,349,120
LIABILITIES								
CURRENT LIABILITIES								
Financial liabilities at fair value through profit or loss	–	99,688	57,714	–	–	83,830	3,890	165,760
Interest payable from swap contracts	–	–	–	–	–	–	–	–
Amounts due to participating dealers	–	–	–	–	733,046	–	–	–
Amounts due to broker	33,747	–	55	43,483	–	–	–	–
Management fee payable	9,766	7,123	12,945	18,983	–	2,422	2,428	6,973
Other payables and accruals	37,817	40,933	40,048	48,482	27,018	20,928	27,379	21,512
Cash collateral liabilities	60,000	20,000	–	–	–	–	–	–
TOTAL LIABILITIES	141,330	167,744	110,762	110,948	760,064	107,180	33,697	194,245
EQUITY								
Net assets attributable to unitholders	3,334,856	3,227,512	2,791,187	2,766,932	701,781	2,234,152	1,375,614	2,154,875
TOTAL LIABILITIES AND EQUITY	3,476,186	3,395,256	2,901,949	2,877,880	1,461,845	2,341,332	1,409,311	2,349,120
Number of units in issue	7,600,000	6,800,000	2,400,000	2,400,000	800,000	2,400,000	2,400,000	4,000,000
Net asset value per unit	0.4388	0.4746	1.1630	1.1529	0.8772	0.9309	0.5732	0.5387

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF FINANCIAL POSITION (continued)

As at 30 June 2023

	CSOP CSI Brokerage Index Daily (2x) Leveraged Product 30 June 2023 (Unaudited) RMB
ASSETS	
CURRENT ASSETS	
Financial assets at fair value through profit or loss	1,465,631
Interest receivable	–
Interest receivable from swap contracts	–
Other receivables	318,103
Amounts due from broker	–
Margin accounts	1,608,899
Cash and cash equivalents	<u>1,996,518</u>
TOTAL ASSETS	<u>5,389,151</u>
LIABILITIES	
CURRENT LIABILITIES	
Financial liabilities at fair value through profit or loss	–
Interest payable from swap contracts	4,039
Amounts due to participating dealers	–
Amounts due to broker	–
Management fee payable	–
Other payables and accruals	187,698
Cash collateral liabilities	<u>–</u>
TOTAL LIABILITIES	<u>191,737</u>
EQUITY	
Net assets attributable to unitholders	<u>5,197,414</u>
TOTAL LIABILITIES AND EQUITY	<u>5,389,151</u>
Number of units in issue	<u>800,000</u>
Net asset value per unit	<u>6.4968</u>

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF FINANCIAL POSITION (continued)

As at 30 June 2023

Note: The Semi-Annual report have applied the accounting policies and methods of computation as per the accompanying notes which are an integral part of these financial statements.

The accompanying notes form an integral part of these unaudited condensed financial statements.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF COMPREHENSIVE INCOME

For the period ended 30 June 2023

	CSOP NASDAQ-100 Index Daily (2x) Leveraged Product		CSOP Gold Futures Daily (2x) Leveraged Product		CSOP CSI 300 Index Daily (2x) Leveraged Product		CSOP CSI 300 Index Daily (-1x) Inverse Product	
	Period from 1 January 2023 to 30 June 2023 (Unaudited) US\$	Period from 1 January 2022 to 30 June 2022 (Unaudited) US\$	Period from 1 January 2023 to 30 June 2023 (Unaudited) US\$	Period from 1 January 2022 to 30 June 2022 (Unaudited) US\$	Period from 1 January 2023 to 30 June 2023 (Unaudited) RMB	Period from 1 January 2022 to 30 June 2022 (Unaudited) RMB	Period from 1 January 2023 to 30 June 2023 (Unaudited) RMB	Period from 1 January 2022 to 30 June 2022 (Unaudited) RMB
INCOME								
Net gains/(losses) on financial assets and financial liabilities at fair value through profit or loss ^{Note 3}	7,471,673	(2,349,511)	13,044,108	(612,773)	(21,872,964)	(56,810,600)	(528,107)	13,030,926
Interest income from bank deposits	61,839	561	728,415	19,662	57,317	30,290	11,006	7,873
Interest income from margin accounts	–	–	18,399	3,397	60,890	30,832	4,275	13,847
Net foreign exchange gains/(losses)	–	–	–	–	5,021,922	3,788,671	549,993	2,931,736
Rebate income	2,853	1,195	60,696	82,245	69,751	177,722	8,692	128,986
Other income	–	13,823	–	–	–	–	195,270	–
TOTAL NET GAIN/(LOSS)	7,536,365	(2,333,932)	13,851,618	(507,469)	(16,663,084)	(52,783,085)	241,129	16,113,368
EXPENSES								
Management fee ^{Note 1, 2}	(83,989)	(30,418)	(1,434,417)	(1,447,858)	(1,715,089)	(1,810,304)	(195,902)	(1,036,456)
Collateral management fee	–	–	(2,991)	(2,924)	(49,375)	(32,915)	(40,009)	(27,129)
Formation fee	–	–	–	–	–	–	–	–
Audit fee	(1,225)	(1,051)	(25,539)	(27,148)	(44,334)	(39,222)	(44,334)	(31,444)
Bank charges	(406)	(1,278)	(482)	(471)	(9,890)	(8,435)	(9,692)	(7,686)
Interest expense	–	(207)	–	(2,902)	–	–	–	–
Index licensing fee	(7,439)	(7,439)	(35,934)	(4,264)	(49,589)	(50,034)	(49,589)	(49,589)
Brokerage and transaction fee	(1,521)	(1,238)	(38,203)	(52,654)	–	(10,622)	–	(4,479)
Interest on margin accounts	–	(228)	(64,604)	(8,005)	(24,495)	(3,639)	–	(195)
Legal and other professional fee	–	–	(2,315)	–	(3,429)	–	(3,429)	–
Other operating expenses	(20,587)	(11,614)	(22,462)	(10,995)	(159,192)	(59,784)	(135,475)	(59,784)
TOTAL OPERATING EXPENSES	(115,167)	(53,473)	(1,626,947)	(1,557,221)	(2,055,393)	(2,014,955)	(478,430)	(1,216,762)
PROFIT/(LOSS) AND TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	7,421,198	(2,387,405)	12,224,671	(2,064,690)	(18,718,477)	(54,798,040)	(237,301)	14,896,606

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF COMPREHENSIVE INCOME (continued)

For the period ended 30 June 2023

	CSOP FTSE China A50 Index Daily (2x) Leveraged Product		CSOP FTSE China A50 Index Daily (-1x) Inverse Product		CSOP Gold Futures Daily (-1x) Inverse Product		CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product	
	Period from 1 January 2023 to 30 June 2023 (Unaudited) US\$	Period from 1 January 2022 to 30 June 2022 (Unaudited) US\$	Period from 1 January 2023 to 30 June 2023 (Unaudited) US\$	Period from 1 January 2022 to 30 June 2022 (Unaudited) US\$	Period from 1 January 2023 to 30 June 2023 (Unaudited) US\$	Period from 19 October 2021 (date of inception) to 30 June 2022 (Unaudited) US\$	Period from 1 January 2023 to 30 June 2023 (Unaudited) US\$	Period from 30 November 2021 (date of inception) to 30 June 2022 (Unaudited) US\$
INCOME								
Net gains/(losses) on financial assets and financial liabilities at fair value through profit or loss ^{Note 3}	(226,655)	(1,065,681)	63,927	1,340,935	(67,907)	(503,916)	290,587	(2,552,605)
Interest income from bank deposits	1,299	48	1,202	772	4,896	439	8,109	471
Interest income from margin accounts	262	292	–	26	–	13	–	–
Net foreign exchange gains/(losses)	(32)	(1,168)	(27)	(1,438)	–	–	–	–
Rebate income	1,924	4,816	1,723	12,950	767	2,685	615	1,767
Other income	–	15,113	5,067	–	21,153	16,897	22,642	18,474
TOTAL NET GAIN/(LOSS)	(223,202)	(1,046,580)	71,892	1,353,245	(41,091)	(483,882)	321,953	(2,531,893)
EXPENSES								
Management fee ^{Note 1, 2}	(23,854)	(50,078)	(18,463)	(138,858)	(8,718)	(49,054)	(12,402)	(33,594)
Collateral management fee	(3,361)	(4,825)	(3,333)	(4,867)	(300)	(1,983)	(300)	(350)
Formation fee	–	–	–	–	–	(77,149)	–	(77,149)
Audit fee	(1,226)	(994)	(3,678)	(3,436)	(5,108)	(8,700)	(5,108)	(8,031)
Bank charges	(402)	(871)	(334)	(591)	(279)	(579)	(427)	(1,118)
Interest expense	–	–	–	–	–	(114)	–	(421)
Index licensing fee	(122)	(7,439)	(710)	(7,439)	(2,264)	(3,471)	(4,657)	(7,676)
Brokerage and transaction fee	–	(107)	–	(559)	(264)	(1,594)	(1,613)	(3,070)
Interest on margin accounts	(530)	(11)	–	(336)	–	(853)	–	–
Legal and other professional fee	–	(1,750)	(610)	(1,750)	(2,315)	–	–	(2,500)
Other operating expenses	(24,087)	(13,963)	(20,509)	(13,963)	(16,141)	(19,978)	(20,325)	(14,321)
TOTAL OPERATING EXPENSES	(53,582)	(80,038)	(47,637)	(171,799)	(35,389)	(163,475)	(44,832)	(148,230)
PROFIT/(LOSS) AND TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	(276,784)	(1,126,618)	24,255	1,181,446	(76,480)	(647,357)	277,121	(2,680,123)

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF COMPREHENSIVE INCOME (continued)

For the period ended 30 June 2023

	CSOP CSI Brokerage Index Daily (2x) Leveraged Product
	Period from 18 October 2022 (date of inception) to 30 June 2023 (Unaudited) <i>RMB</i>
INCOME	
Net gains/(losses) on financial assets and financial liabilities at fair value through profit or loss ^{Note 3}	1,424,690
Interest income from bank deposits	4,032
Interest income from margin accounts	8,899
Net foreign exchange gains/(losses)	–
Rebate income	10,356
Other income	298,399
TOTAL NET GAIN/(LOSS)	<u>1,746,376</u>
EXPENSES	
Management fee ^{Note 1, 2}	(150,759)
Collateral management fee	(17,608)
Formation fee	(338,953)
Audit fee	(62,036)
Bank charges	(18,185)
Interest expense	–
Index licensing fee	(73,252)
Brokerage and transaction fee	–
Interest on margin accounts	–
Legal and other professional fee	–
Other operating expenses	(137,871)
TOTAL OPERATING EXPENSES	<u>(798,664)</u>
PROFIT/(LOSS) AND TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	
	<u><u>947,712</u></u>

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF COMPREHENSIVE INCOME (continued)

For the period ended 30 June 2023

Note 1 During the period ended 30 June 2023, the Trustee fee and Registrar's fee are included in the Management fee and the Manager will pay the fees of the Trustee and Registrar out of the management fee.

Note 2 During the period ended 30 June 2023, other than Management fee that paid to the Manager, no other amounts are paid to the Manager/connected person of Manager.

Note 3 During the period ended 30 June 2023, Swap Fees are included in the Net gains/(losses) on financial assets and financial liabilities at fair value through profit or loss.

The accompanying notes form an integral part of these unaudited condensed financial statements.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO UNITHOLDERS

For the period ended 30 June 2023

	CSOP NASDAQ-100 Index Daily (2x) Leveraged Product		CSOP Gold Futures Daily (2x) Leveraged Product		CSOP CSI 300 Index Daily (2x) Leveraged Product		CSOP CSI 300 Index Daily (-1x) Inverse Product	
	Period from 1 January 2023 to 30 June 2023 US\$	Period from 1 January 2022 to 30 June 2022 US\$	Period from 1 January 2023 to 30 June 2023 US\$	Period from 1 January 2022 to 30 June 2022 US\$	Period from 1 January 2023 to 30 June 2023 RMB	Period from 1 January 2022 to 30 June 2022 RMB	Period from 1 January 2023 to 30 June 2023 RMB	Period from 1 January 2022 to 30 June 2022 RMB
Net assets attributable to unitholders at the beginning of the period	9,163,704	2,298,329	193,609,090	234,143,141	202,487,476	269,139,600	25,674,341	155,561,135
Issue of units	3,936,832	14,421,978	3,006,365	20,081,857	18,257,319	80,652,044	9,860,320	–
Redemption of units	(5,603,220)	(4,519,266)	(38,899,372)	(85,560,653)	–	(30,957,491)	(9,917,719)	(86,215,175)
Net issue of units	(1,666,388)	9,902,712	(35,893,007)	(65,478,796)	18,257,319	49,694,553	(57,399)	(86,215,175)
Profit/(loss) and total comprehensive income for the period	7,421,198	(2,387,405)	12,224,671	(2,064,690)	(18,718,477)	(54,798,040)	(237,301)	14,896,606
Net assets attributable to unitholders at the end of the period	<u>14,918,514</u>	<u>9,813,636</u>	<u>169,940,754</u>	<u>166,599,655</u>	<u>202,026,318</u>	<u>264,036,113</u>	<u>25,379,641</u>	<u>84,242,566</u>
Number of units in issue at the beginning of the period	8,020,000	820,000	212,200,000	234,600,000	45,200,000	33,200,000	4,000,000	28,000,000
Issue of units	3,200,000	8,800,000	3,200,000	20,000,000	4,000,000	12,800,000	1,600,000	–
Redemption of units	(4,000,000)	(2,400,000)	(37,600,000)	(77,600,000)	–	(4,800,000)	(1,600,000)	(13,600,000)
Number of units in issue at the end of the period	<u>7,220,000</u>	<u>7,220,000</u>	<u>177,800,000</u>	<u>177,000,000</u>	<u>49,200,000</u>	<u>41,200,000</u>	<u>4,000,000</u>	<u>14,400,000</u>

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO UNITHOLDERS (continued)

For the period ended 30 June 2023

	CSOP FTSE China A50 Index Daily (2x) Leveraged Product		CSOP FTSE China A50 Index Daily (-1x) Inverse Product		CSOP Gold Futures Daily (-1x) Inverse Product		CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product	
	Period from 1 January 2023 to 30 June 2023 US\$	Period from 1 January 2022 to 30 June 2022 US\$	Period from 1 January 2023 to 30 June 2023 US\$	Period from 1 January 2022 to 30 June 2022 US\$	Period from 1 January 2023 to 30 June 2023 US\$	Period from 19 October 2021 (date of inception) to 30 June 2022 US\$	Period from 1 January 2023 to 30 June 2023 US\$	Period from 30 November 2021 (date of inception) to 30 June 2022 US\$
Net assets attributable to unitholders at the beginning of the period	3,227,512	7,116,407	2,766,932	22,905,976	2,234,152	–	2,154,875	–
Issue of units	384,128	2,313,701	–	–	–	12,000,000	426,101	9,941,321
Redemption of units	–	(2,086,782)	–	(15,739,638)	(1,455,891)	(9,894,776)	(1,482,483)	(1,517,660)
Net issue of units	384,128	226,919	–	(15,739,638)	(1,455,891)	2,105,224	(1,056,382)	8,423,661
Profit/(loss) and total comprehensive income for the period	(276,784)	(1,126,618)	24,255	1,181,446	(76,480)	(647,357)	277,121	(2,680,123)
Net assets attributable to unitholders at the end of the period	<u>3,334,856</u>	<u>6,216,708</u>	<u>2,791,187</u>	<u>8,347,784</u>	<u>701,781</u>	<u>1,457,867</u>	<u>1,375,614</u>	<u>5,743,538</u>
Number of units in issue at the beginning of the period	6,800,000	10,000,000	2,400,000	21,600,000	2,400,000	–	4,000,000	–
Issue of units	800,000	3,600,000	–	–	–	12,000,000	800,000	14,400,000
Redemption of units	–	(4,000,000)	–	(13,600,000)	(1,600,000)	(10,400,000)	(2,400,000)	(2,400,000)
Number of units in issue at the end of the period	<u>7,600,000</u>	<u>9,600,000</u>	<u>2,400,000</u>	<u>8,000,000</u>	<u>800,000</u>	<u>1,600,000</u>	<u>2,400,000</u>	<u>12,000,000</u>

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO UNITHOLDERS (continued)

For the period ended 30 June 2023

	CSOP CSI Brokerage Index Daily (2x) Leveraged Product
	Period from 18 October 2022 (date of inception) to 30 June 2023 <i>RMB</i>
Net assets attributable to unitholders at the beginning of the period	—
Issue of units	50,915,778
Redemption of units	<u>(46,666,076)</u>
Net issue of units	4,249,702
Profit/(loss) and total comprehensive income for the period	<u>947,712</u>
Net assets attributable to unitholders at the end of the period	<u><u>5,197,414</u></u>
Number of units in issue at the beginning of the period	—
Issue of units	7,200,000
Redemption of units	<u>(6,400,000)</u>
Number of units in issue at the end of the period	<u><u>800,000</u></u>

The accompanying notes form an integral part of these unaudited condensed financial statements.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF CASH FLOWS

For the period ended 30 June 2023

CSOP NASDAQ-100 Index Daily (2x) Leveraged Product

Period from 1 January 2023 to 30 June 2023 (Unaudited) US\$	Period from 1 January 2022 to 30 June 2022 (Unaudited) US\$
---	---

CASH FLOWS FROM OPERATING ACTIVITIES

Profit/(loss) for the period	7,421,198	(2,387,405)
Adjustments for:		
Interest on margin accounts	–	228
Interest income from bank deposits	(61,839)	(561)
Operating cash flows before movements in working capital	<u>7,359,359</u>	<u>(2,387,738)</u>
Increase in financial assets at fair value through profit or loss	(697,676)	(1,417,345)
Decrease/(increase) in other receivables	958	(13,113)
Increase in amounts due from broker	–	(4,505)
Decrease/(increase) in margin accounts	332,103	(1,492,777)
Decrease in financial liabilities at fair value through profit or loss	(1,143,284)	–
Increase in management fee payable	19,812	11,394
Decrease in other payables and accruals	(7,118)	(10,035)
Cash generated from/(used in) operations	<u>5,864,154</u>	<u>(5,314,119)</u>
Interest received on bank deposits	61,832	589
Interest paid on margin accounts	–	(228)
Net cash flows generated from/(used in) operating activities	<u>5,925,986</u>	<u>(5,313,758)</u>

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from issue of units	3,936,832	14,421,978
Payments on redemption of units	(5,603,220)	(4,519,266)
Net cash flows generated from/(used in) financing activities	<u>(1,666,388)</u>	<u>9,902,712</u>

NET INCREASE IN CASH AND CASH EQUIVALENTS

Cash and cash equivalents at the beginning of the period	4,259,598	4,588,954
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	<u>4,990,020</u>	<u>1,342,546</u>
	<u>9,249,618</u>	<u>5,931,500</u>

Analysis of balances of cash and cash equivalents

Term deposits with original maturity less than three months	100,182	–
Bank balances	9,149,436	5,931,500
Cash and cash equivalents as stated in the statement of cash flows	<u>9,249,618</u>	<u>5,931,500</u>

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF CASH FLOWS (continued)

For the period ended 30 June 2023

CSOP Gold Futures Daily (2x) Leveraged Product

Period from 1 January 2023 to 30 June 2023 (Unaudited) US\$	Period from 1 January 2022 to 30 June 2022 (Unaudited) US\$
---	---

CASH FLOWS FROM OPERATING ACTIVITIES

Profit/(loss) for the period	12,224,671	(2,064,690)
Adjustments for:		
Interest on margin accounts	64,604	8,005
Interest income from bank deposits	(728,415)	(19,662)
Interest income from margin accounts	(18,399)	(3,397)
Operating cash flows before movements in working capital	<u>11,542,461</u>	<u>(2,079,744)</u>
Decrease in financial assets at fair value through profit or loss	24,611,392	16,048,234
Decrease in other receivables	7,146	10,283
(Increase)/decrease in margin accounts	(9,484,510)	18,118,924
Increase/(decrease) in financial liabilities at fair value through profit or loss	6,747,291	(565,224)
Increase/(decrease) in management fee payable	3,892	(174,557)
Increase in other payables and accruals	28,180	15,428
Decrease in cash collateral liabilities	(1,520,000)	(50,000)
Cash generated from operations	<u>31,935,852</u>	<u>31,323,344</u>
Interest received on bank deposits	730,943	22,666
Interest paid on margin accounts	(46,205)	(4,608)
Net cash flows generated from/(used in) operating activities	<u>32,620,590</u>	<u>31,341,402</u>

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from issue of units	3,006,365	19,328,705
Payments on redemption of units	(38,899,372)	(85,560,653)
Net cash flows generated from/(used in) financing activities	<u>(35,893,007)</u>	<u>(66,231,948)</u>

NET DECREASE IN CASH AND CASH EQUIVALENTS

Cash and cash equivalents at the beginning of the period	<u>101,971,880</u>	<u>128,529,267</u>
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	<u>98,699,463</u>	<u>93,638,721</u>

Analysis of balances of cash and cash equivalents

Term deposits with original maturity less than three months	8,705,590	–
Bank balances	<u>89,993,873</u>	<u>93,638,721</u>
Cash and cash equivalents as stated in the statement of cash flows	<u>98,699,463</u>	<u>93,638,721</u>

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF CASH FLOWS (continued)

For the period ended 30 June 2023

CSOP CSI 300 Index Daily (2x) Leveraged Product

Period from 1 January 2023 to 30 June 2023 (Unaudited) RMB	Period from 1 January 2022 to 30 June 2022 (Unaudited) RMB
--	--

CASH FLOWS FROM OPERATING ACTIVITIES

Profit/(loss) for the period	(18,718,477)	(54,798,040)
Adjustments for:		
Interest on margin accounts	24,495	3,639
Interest income from bank deposits	(57,317)	(30,290)
Interest income from margin accounts	(60,890)	(30,832)
Operating cash flows before movements in working capital	(18,812,189)	(54,855,523)
(Increase)/decrease in financial assets at fair value through profit or loss	(4,002,739)	66,536,302
Decrease in other receivables	3,743	70,325
Increase in margin accounts	(221,186)	(2,307,603)
(Decrease)/increase in financial liabilities at fair value through profit or loss	(1,876,829)	165,706
Increase/(decrease) in management fee payable	29,853	(188,107)
Increase/(decrease) in cash collateral liabilities	1,600,000	(3,350,416)
Decrease in interest payable from swap contracts	(439,877)	(356,742)
(Decrease)/increase in other payables and accruals	(165,285)	3,766
Cash (used in)/generated from operations	(23,884,509)	5,717,708
Interest received on bank deposits	57,317	30,290
Interest received on margin accounts	36,395	27,193
Net cash flows generated from/(used in) operating activities	(23,790,797)	5,775,191

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from issue of units	18,257,319	80,652,044
Payments on redemption of units	–	(30,957,491)
Net cash flows generated from/(used in) financing activities	18,257,319	49,694,553

NET (DECREASE) IN CASH AND CASH EQUIVALENTS

Cash and cash equivalents at the beginning of the period	81,477,647	62,960,277
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	75,944,169	118,430,021

Analysis of balances of cash and cash equivalents

Bank balances	75,944,169	118,430,021
Cash and cash equivalents as stated in the statement of cash flows	75,944,169	118,430,021

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF CASH FLOWS (continued)

For the period ended 30 June 2023

	CSOP CSI 300 Index Daily (-1x) Period from 1 January 2023 to 30 June 2023 (Unaudited) RMB	Inverse Product Period from 1 January 2022 to 30 June 2022 (Unaudited) RMB
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit/(loss) for the period	(237,301)	14,896,606
Adjustments for:		
Interest on margin accounts	–	195
Interest income from bank deposits	(11,006)	(7,873)
Interest income from margin accounts	(4,275)	(13,847)
Operating cash flows before movements in working capital	(252,582)	14,875,081
(Increase)/decrease in financial assets at fair value through profit or loss	(2,727,941)	26,216,615
Increase in interest receivable from swap contracts	(1,854)	–
(Increase)/decrease in other receivables	(187,305)	13,661
Decrease in amounts due from broker	806	–
Decrease in margin accounts	1,584,004	8,870,543
Increase/(decrease) in financial liabilities at fair value through profit or loss	182,289	(1,097,664)
Decrease in interest payable from swap contracts	–	(110,772)
Decrease in management fee payable	(178,930)	(214,103)
Increase in amounts due to broker	2,206	7,353
Decrease in cash collateral liabilities	–	(100,000)
Decrease in other payables and accruals	(127,964)	(9,020)
Cash (used in)/generated from operations	(1,707,271)	48,451,694
Interest received on bank deposits	11,006	17,329
Interest received on margin accounts	4,275	13,652
Net cash flows generated from/(used in) operating activities	(1,691,990)	48,482,675
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issue of units	9,860,320	2,200
Payments on redemption of units	(9,917,719)	(95,197,583)
Net cash flows generated from/(used in) financing activities	(57,399)	(95,195,383)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(1,749,389)	(46,712,708)
Cash and cash equivalents at the beginning of the period	15,836,306	65,026,037
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	14,086,917	18,313,329
Analysis of balances of cash and cash equivalents		
Bank balances	14,086,917	18,313,329
Cash and cash equivalents as stated in the statement of cash flows	14,086,917	18,313,329

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF CASH FLOWS (continued)

For the period ended 30 June 2023

CSOP FTSE China A50 Index Daily (2x) Leveraged Product

Period from 1 January 2023 to 30 June 2023 (Unaudited) US\$	Period from 1 January 2022 to 30 June 2022 (Unaudited) US\$
---	---

CASH FLOWS FROM OPERATING ACTIVITIES

Profit/(loss) for the period	(276,784)	(1,126,618)
Adjustments for:		
Interest on margin accounts	530	11
Interest income from bank deposits	(1,299)	(48)
Interest income from margin accounts	(262)	(292)
Operating cash flows before movements in working capital	(277,815)	(1,126,947)
(Increase)/decrease in financial assets at fair value through profit or loss	(154,202)	787,595
Decrease/(increase) in other receivables	4,367	(14,336)
Decrease/(increase) in amounts due from broker	85,346	(219,051)
(Increase)/decrease in margin accounts	(31,907)	145,568
Decrease in financial liabilities at fair value through profit or loss	(99,688)	(160,077)
Increase/(decrease) in management fee payable	2,643	(8,994)
Increase in cash collateral liabilities	40,000	450,000
Increase/(decrease) amounts due to broker	33,747	(38,723)
Decrease in other payables and accruals	(3,116)	(6,128)
Cash used in operations	(400,625)	(191,093)
Interest received on bank deposits	1,284	79
Interest (paid)/received on margin accounts	(268)	281
Net cash flows generated from/(used in) operating activities	(399,609)	(190,733)

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from issue of units	384,128	2,313,701
Payments on redemption of units	–	(2,086,782)
Net cash flows generated from/(used in) financing activities	384,128	226,919

NET (DECREASE) IN CASH AND CASH EQUIVALENTS

Cash and cash equivalents at the beginning of the period	1,779,545	3,349,200
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	1,764,064	3,385,386

Analysis of balances of cash and cash equivalents

Term deposits with original maturity less than three months	100,232	–
Bank balances	1,663,832	3,385,386
Cash and cash equivalents as stated in the statement of cash flows	1,764,064	3,385,386

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF CASH FLOWS (continued)

For the period ended 30 June 2023

CSOP FTSE China A50 Index Daily (-1x) Inverse Product

Period from 1 January 2023 to 30 June 2023 (Unaudited) US\$	Period from 1 January 2022 to 30 June 2022 (Unaudited) US\$
---	---

CASH FLOWS FROM OPERATING ACTIVITIES

Profit/(loss) for the period	24,255	1,181,446
Adjustments for:		
Interest on margin accounts	–	336
Interest income from bank deposits	(1,202)	(772)
Interest income from margin accounts	–	(26)
Operating cash flows before movements in working capital	23,053	1,180,984
Decrease in financial assets at fair value through profit or loss	23,047	5,828,445
(Increase)/decrease in other receivables	(3,265)	2,908
(Increase)/decrease in amounts due from broker	(15,354)	55,011
(Increase)/decrease in margin accounts	(6,221)	622,619
Increase in financial liabilities at fair value through profit or loss	57,714	166,927
(Decrease)/increase in amounts due to broker	(43,428)	163,756
Decrease in management fee payable	(6,038)	(34,989)
Decrease in cash collateral liabilities	–	(160,000)
Decrease in other payables and accruals	(8,434)	(4,681)
Cash generated from operations	21,074	7,820,980
Interest received on bank deposits	1,202	1,091
Interest paid on margin accounts	–	(310)
Net cash flows generated from/(used in) operating activities	22,276	7,821,761

CASH FLOWS FROM FINANCING ACTIVITIES

Payments on redemption of units	–	(15,739,638)
Net cash flows generated from/(used in) financing activities	–	(15,739,638)

NET INCREASE IN CASH AND CASH EQUIVALENTS

Cash and cash equivalents at the beginning of the period	1,655,503	11,936,968
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	1,677,779	4,019,091

Analysis of balances of cash and cash equivalents

Bank balances	1,677,779	4,019,091
Cash and cash equivalents as stated in the statement of cash flows	1,677,779	4,019,091

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF CASH FLOWS (continued)

For the period ended 30 June 2023

CSOP Gold Futures Daily (-1x) Inverse Product

	Period from 1 January 2023 to 30 June 2023 (Unaudited) US\$	Period from 19 October 2021 (date of inception) to 30 June 2022 (Unaudited) US\$
--	---	---

CASH FLOWS FROM OPERATING ACTIVITIES

Profit/(loss) for the period	(76,480)	(647,357)
Adjustments for:		
Interest on margin accounts	–	853
Interest income from bank deposits	(4,896)	(439)
Interest income from margin accounts	–	(13)
Operating cash flows before movements in working capital	(81,376)	(646,956)
Decrease/(increase) in financial assets at fair value through profit or loss	205,315	(341,255)
Increase in other receivables	(23,078)	(17,208)
Increase in amounts due from broker	(321,776)	–
Decrease/(increase) in margin accounts	318,303	(192,644)
(Decrease)/increase in management fee payable	(2,422)	5,007
Increase in formation fee payable	–	27,227
Increase in other payables and accruals	6,090	22,659
Cash generated from/(used in) operations	101,056	(1,143,170)
Interest received on bank deposits	4,896	439
Interest paid on margin accounts	–	(840)
Net cash flows generated from/(used in) operating activities	105,952	(1,143,571)

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from issue of units	–	12,000,000
Payments on redemption of units	(722,845)	(9,894,776)
Net cash flows generated from/(used in) financing activities	(722,845)	2,105,224

NET (DECREASE) IN CASH AND CASH EQUIVALENTS

Cash and cash equivalents at the beginning of the period	1,485,067	–
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	868,174	961,653

Analysis of balances of cash and cash equivalents

Bank balances	868,174	961,653
Cash and cash equivalents as stated in the statement of cash flows	868,174	961,653

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF CASH FLOWS (continued)

For the period ended 30 June 2023

CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product

	Period from 1 January 2023 to 30 June 2023 (Unaudited) US\$	Period from 30 November 2021 (date of inception) to 30 June 2022 (Unaudited) US\$
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit/(loss) for the period	277,121	(2,680,123)
Adjustments for:		
Interest income from bank deposits	(8,109)	(471)
Operating cash flows before movements in working capital	<u>269,012</u>	<u>(2,680,594)</u>
Decrease/(increase) in financial assets at fair value through profit or loss	111,938	(1,303,727)
Increase in other receivables	(20,745)	(19,049)
Decrease/(increase) in margin accounts	304,828	(767,228)
Decrease in financial liabilities at fair value through profit or loss	(161,870)	–
(Decrease)/increase in management fee payable	(4,545)	12,536
Increase in formation fee payable	–	25,251
Increase in other payables and accruals	5,867	21,900
Cash generated from/(used in) operations	<u>504,485</u>	<u>(4,710,911)</u>
Interest received on bank deposits	8,104	471
Net cash flows generated from/(used in) operating activities	<u>512,589</u>	<u>(4,710,440)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issue of units	426,101	9,941,321
Payments on redemption of units	(1,482,483)	(1,517,660)
Net cash flows generated from/(used in) financing activities	<u>(1,056,382)</u>	<u>8,423,661</u>
NET (DECREASE) IN CASH AND CASH EQUIVALENTS	(543,793)	3,713,221
Cash and cash equivalents at the beginning of the period	<u>1,374,622</u>	–
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	<u>830,829</u>	<u>3,713,221</u>
Analysis of balances of cash and cash equivalents		
Term deposits with original maturity less than three months	79,072	–
Bank balances	<u>751,757</u>	<u>3,713,221</u>
Cash and cash equivalents as stated in the statement of cash flows	<u>830,829</u>	<u>3,713,221</u>

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED STATEMENT OF CASH FLOWS (continued)

For the period from 18 October 2022 (date of inception) to 30 June 2023

	CSOP CSI Brokerage Index Daily (2x) Leveraged Product Period from 18 October 2022 (date of inception) to 30 June 2023 (Unaudited) <i>RMB</i>
CASH FLOWS FROM OPERATING ACTIVITIES	
Profit/(loss) for the period	947,712
Adjustments for:	
Interest on margin accounts	–
Interest income from bank deposits	(4,032)
Interest income from margin accounts	(8,899)
Operating cash flows before movements in working capital	<u>934,781</u>
Increase in financial assets at fair value through profit or loss	(1,465,631)
Increase in other receivables	(318,103)
Increase in margin accounts	(1,608,899)
Increase in interest payable from swap contracts	4,039
Increase in other payables and accruals	187,698
Cash used in operations	<u>(2,266,115)</u>
Interest received on bank deposits	4,032
Interest received on margin accounts	8,899
Net cash flows generated from/(used in) operating activities	<u>(2,253,184)</u>
CASH FLOWS FROM FINANCING ACTIVITIES	
Proceeds from issue of units	50,915,778
Payments on redemption of units	(46,666,076)
Net cash flows generated from/(used in) financing activities	<u>4,249,702</u>
NET INCREASE IN CASH AND CASH EQUIVALENTS	1,996,518
Cash and cash equivalents at the beginning of the period	–
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	<u>1,996,518</u>
Analysis of balances of cash and cash equivalents	
Bank balances	<u>1,996,518</u>
Cash and cash equivalents as stated in the statement of cash flows	<u>1,996,518</u>

The accompanying notes form an integral part of these unaudited condensed financial statements.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

1. GENERAL INFORMATION

CSOP Leveraged and Inverse Series II (the “Trust”) is an umbrella unit trust governed by its trust deed dated 24 April 2020, as amended by the supplemental deeds on 24 April 2020, 19 May 2020, 10 July 2020, 23 December 2020, 20 September 2021, 15 October 2021 and 21 September 2022 (collectively, the “Trust Deed”) between CSOP Asset Management Limited (the “Manager”) and Cititrust Limited (the “Trustee”). It is authorised by the Securities and Futures Commission of Hong Kong (the “SFC”) pursuant to Section 104(1) of the Securities and Futures Ordinance of Hong Kong (the “SFO”).

As of 30 June 2023, the Trust has nine sub-funds, each a separate sub-fund of the Trust, which are authorised by the Securities and Futures Commission of Hong Kong (the “SFC”) pursuant to section 104(1) of the SFO. The nine sub-funds, including CSOP NASDAQ-100 Index Daily (2x) Leveraged Product, CSOP Gold Futures Daily (2x) Leveraged Product, CSOP CSI 300 Index Daily (2x) Leveraged Product, CSOP CSI 300 Index Daily (-1x) Inverse Product, CSOP FTSE China A50 Index Daily (2x) Leveraged Product, CSOP FTSE China A50 Index Daily (-1x) Inverse Product, CSOP Gold Futures Daily (-1x) Inverse Product, CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product and CSOP CSI Brokerage Index Daily (2x) Leveraged Product are referred to individually or collectively as the “Sub-Fund(s)”. The Sub-Funds are listed on the Stock Exchange of Hong Kong Limited (the “SEHK”) with details below:

<u>Name of Sub-Funds</u>	<u>Listing date on the SEHK</u>
CSOP NASDAQ-100 Index Daily (2x) Leveraged Product	15 May 2020
CSOP Gold Futures Daily (2x) Leveraged Product	5 June 2020
CSOP CSI 300 Index Daily (2x) Leveraged Product	27 July 2020
CSOP CSI 300 Index Daily (-1x) Inverse Product	27 July 2020
CSOP FTSE China A50 Index Daily (2x) Leveraged Product	20 January 2021
CSOP FTSE China A50 Index Daily (-1x) Inverse Product	20 January 2021
CSOP Gold Futures Daily (-1x) Inverse Product	20 October 2021
CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product	1 December 2021
CSOP CSI Brokerage Index Daily (2x) Leveraged Product	19 October 2022

CSOP NASDAQ-100 Index Daily (2x) Leveraged Product

The investment objective of CSOP NASDAQ-100 Index Daily (2x) Leveraged Product (stock code: 7266) is to provide investment results that, before fees and expenses, closely correspond to twice (2x) the daily performance of the NASDAQ-100 Index (the “Index”). To achieve the investment objective of the Sub-Fund, the Manager will adopt a futures-based replication strategy through investing directly in the nearest quarter E-Mini NASDAQ 100 Futures (“E-mini NASDAQ 100 Futures”) which are traded on the Chicago Mercantile Exchange (“CME”), subject to the rolling strategy discussed below, to obtain the required exposure to the Index.

As the Index is not a futures index, the Sub-Fund does not follow any predetermined roll-over schedule. The Manager will use its discretion to carry out the roll-over of the nearest quarter E-mini NASDAQ 100 Futures into the next quarter E-mini NASDAQ 100 Futures with the goal that, by one business day before the last trading day of the nearest quarter E-mini NASDAQ 100 Futures, all roll-over activities would have occurred. The roll will occur within a 8-calendar days period in the last calendar month of each quarter.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

1. GENERAL INFORMATION (CONTINUED)

CSOP Gold Futures Daily (2x) Leveraged Product

The investment objective of CSOP Gold Futures Daily (2x) Leveraged Product (stock code: 7299) is to provide investment results that, before fees and expenses, closely correspond to twice (2x) the daily performance of the Solactive Gold 1-Day Rolling Futures Index (the “Index”). To achieve the investment objective of the Sub-Fund, the Manager will use a combination of a futures-based replication strategy and a swap-based synthetic replication strategy. The Manager will adopt a futures-based replication strategy through investing directly in the Active Contracts of gold futures traded on the New York Commodity Exchange (COMEX) (“COMEX Gold Futures”) subject to the rolling strategy to obtain the required exposure to the Index and use a swap-based synthetic replication strategy by investing in swaps.

Rolling strategy is defined whereby the Manager will generally carry out the roll-over of the Active Contracts into Next Active Contracts according to the roll-over schedule in respect of the Index with the goal that, by one business day before the last trading day of the previous Active Contracts, all roll-over activities would have occurred in one Business Day. Under exceptional circumstances, the Manager will use its discretion to deviate from the roll-over schedule in the best interests of the Sub-Fund and the Unitholders.

CSOP CSI 300 Index Daily (2x) Leveraged Product

The investment objective of CSOP CSI 300 Index Daily (2x) Leveraged Product (stock code: 7233) is to provide investment results that, before fees and expenses, closely correspond to twice (2x) the daily performance of the CSI 300 Index (the “Index”).

The Manager intends to adopt a swap-based synthetic replication strategy to achieve the investment objective of the Sub-Fund, pursuant to which the Sub-Fund will enter into more than one partially-funded swap (which are over-the counter financial derivative instruments entered into with more than one swap Counterparty) whereby the Sub-Fund will provide a portion of the net proceeds from subscription from the issue of the Units as initial margin (“Initial Amount”) to the swap Counterparties which will be held by the custodian appointed by the Trustee in a segregated account and will only be transferred to the swap Counterparties when the Sub-Fund defaults and in return the swap counterparties will provide the Sub-Fund with an exposure to the Index (net of transaction costs).

CSOP CSI 300 Index Daily (-1x) Inverse Product

The investment objective of CSOP CSI 300 Index Daily (-1x) Inverse Product (stock code: 7333) is to provide investment results that, before fees and expenses, closely correspond to inverse (-1x) the daily performance of the CSI 300 Index (the “Index”).

The Manager intends to adopt a swap-based synthetic replication strategy to achieve the investment objective of the Sub-fund, pursuant to which the Sub-Fund will enter into more than one partially-funded Swap (which are over-the counter financial derivative instruments entered into with more than one swap counterparty) whereby the Sub-Fund will provide a portion of the net proceeds from subscription from the issue of the Units as initial margin (“Initial Amount”) to the Swap Counterparties which will be held by the custodian appointed by the Trustee in a segregated account and will only be transferred to the Swap Counterparties when the Sub-Fund defaults and in return the Swap Counterparties will provide the Sub-Fund with an exposure to the Index (net of transaction costs).

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

1. GENERAL INFORMATION (CONTINUED)

CSOP FTSE China A50 Index Daily (2x) Leveraged Product

The investment objective of CSOP FTSE China A50 Index Daily (2x) Leveraged Product (stock code: 7248) is to provide investment results that, before fees and expenses, closely correspond to twice (2x) the daily performance of the FTSE China A50 Index (the “Index”).

The Manager intends to adopt a Swap-based synthetic replication strategy to achieve the investment objective of the Sub-Fund, pursuant to which the Sub-Fund will enter into more than one partially-funded swap (which are over-the counter financial derivative instruments entered into with more than one swap counterparty) whereby the Sub-Fund will provide a portion of the net proceeds from subscription from the issue of the Units as initial margin (“Initial Amount”) to the swap counterparties which will be held by the custodian appointed by the Trustee in a segregated account and will only be transferred to the swap counterparties when the Sub-Fund defaults and in return the swap counterparties will provide the Sub-Fund with an exposure to the Index (net of transaction costs).

CSOP FTSE China A50 Index Daily (-1x) Inverse Product

The investment objective of CSOP FTSE China A50 Index Daily (-1x) Inverse Product (stock code: 7348) is to provide investment results that, before fees and expenses, closely correspond to the inverse (-1x) the daily performance of the FTSE China A50 Index (the “Index”).

The Manager intends to adopt a swap-based synthetic replication strategy to achieve the investment objective of the Sub-Fund, pursuant to which the Sub-Fund will enter into more than one partially-funded Swap (which are over-the counter financial derivative instruments entered into with more than one swap counterparty) whereby the Sub-Fund will provide a portion of the net proceeds from subscription from the issue of the Units as initial margin (“Initial Amount”) to the swap counterparties which will be held by the custodian appointed by the Trustee in a segregated account and will only be transferred to the swap counterparties when the Sub-Fund defaults and in return the swap counterparties will provide the Sub-Fund with an exposure to the Index (net of transaction costs).

CSOP Gold Futures Daily (-1x) Inverse Product

The investment objective of CSOP Gold Futures Daily (-1x) Inverse Product (stock code: 7374) is to provide investment results that, before fees and expenses, closely correspond to the inverse (-1x) of the daily performance of the Solactive Gold 1-Day Rolling Futures Index (the “Index”). The Index consists of only gold futures whose price movements may deviate significantly from the gold spot price. The Sub-Fund does not seek to deliver an inverse return of gold spot price.

To achieve the investment objective of the Sub-Fund, the Manager will use a combination of a futures-based replication strategy and a swap-based synthetic replication strategy. The Manager will adopt a futures-based replication strategy through investing directly in the Active Contracts of gold futures traded on the New York Commodity Exchange (COMEX) (“COMEX Gold Futures”) subject to the rolling strategy to obtain the required exposure to the Index and use a swap-based synthetic replication strategy by investing in swaps.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

1. GENERAL INFORMATION (CONTINUED)

CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product

The investment objective of CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product (stock code: 7345) is to provide investment results that, before fees and expenses, closely correspond to the inverse (-1x) of the daily performance of the Solactive WTI 1-Day Rolling Futures Index (the “Index”). The Index consists of only crude oil futures whose price movements may deviate significantly from the WTI crude oil spot price. The Sub-Fund does not seek to deliver an inverse return of WTI crude oil spot price.

To achieve the investment objective of the Sub-Fund, the Manager will use a combination of a futures-based replication strategy and a swap-based synthetic replication strategy. The Manager will adopt a futures-based replication strategy through investing directly in the Active Contracts of West Texas Intermediate crude oil (“WTI crude oil”) (also known as Texas light sweet crude oil) futures traded on the New York Mercantile Exchange (NYMEX) (“WTI Futures Contracts”) subject to the rolling strategy subject to the rolling strategy to obtain the required exposure to the Index and use a swap-based synthetic replication strategy by investing in Swaps.

CSOP CSI Brokerage Index Daily (2x) Leveraged Product

The investment objective of CSOP CSI Brokerage Index Daily (2x) Leveraged Product (stock code: 7252) is to provide investment results that, before fees and expenses, closely correspond to twice (2x) the Daily performance of the CSI All Share Investment Banking & Brokerage Index (the “Index”).

The Manager intends to adopt a Swap-based synthetic replication strategy to achieve the investment objective of the Product, pursuant to which the Product will enter into more than one partially-funded Swap (which are over-the-counter financial derivative instruments entered into with more than one Swap Counterparty) whereby the Product will provide a portion of the net proceeds from subscription from the issue of the Units as initial margin (“Initial Amount”) to the Swap Counterparties which will be held by the custodian appointed by the Trustee in segregated accounts and will only be transferred to the Swap Counterparties when the Product defaults and in return the Swap Counterparties will provide the Product with an exposure to the Index (net of transaction costs).

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

(a)(i) Basis of preparation

The financial statements of the Sub-Funds have been prepared in accordance with International Financial Reporting Standards (“IFRSs”) as issued by the International Accounting Standards Board (“IASB”), and interpretations issued by the International Financial Reporting Interpretations Committee of the IASB and the relevant disclosure provisions of the Trust Deed and the relevant disclosure provisions specified in Appendix E of the *Code on Unit Trusts and Mutual Funds* of the SFC (the “SFC Code”).

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

(a)(i) Basis of preparation (continued)

The financial statements have been prepared under the historical cost convention, except for financial assets and liabilities classified as at fair value through profit or loss (“FVPL”) that have been measured at fair value. The financial statements are presented in United States dollars (“US\$”) for CSOP NASDAQ-100 Index Daily (2x) Leveraged Product, CSOP Gold Futures Daily (2x) Leveraged Product, CSOP FTSE China A50 Index Daily (2x) Leveraged Product, CSOP FTSE China A50 Index Daily (-1x) Inverse Product, CSOP Gold Futures Daily (-1x) Inverse Product, CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product, CSOP CSI 300 Index Daily (2x) Leveraged Product, CSOP CSI 300 Index Daily (-1x) Inverse Product and CSOP CSI Brokerage Index Daily (2x) Leveraged Product. All values are rounded to the nearest US\$ and RMB except where otherwise indicated.

CSOP CSI Brokerage Index Daily (2x) Leveraged Product has adopted for the first time all applicable and effective IFRSs.

(a)(ii) Significant accounting judgements, estimates and assumptions

The preparation of financial statements, in conformity with IFRSs, requires the management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts recognised in the financial statements and disclosure of contingent liabilities. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

(a)(iii) Issued but not yet effective IFRSs

The Sub-Funds have not early applied any of the new and revised IFRSs that have been issued but are not yet effective for the accounting period ended 30 June 2023 in these financial statements. Among the new and revised IFRSs, the following is expected to be relevant to the Sub-Funds’ financial statements upon becoming effective:

Definition of Accounting Estimates – Amendments to IAS 8

In February 2021, the IASB issued amendments to IAS 8, in which it introduces a definition of ‘accounting estimates’. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, they clarify how entities use measurement techniques and inputs to develop accounting estimates.

The amendments are effective for annual reporting periods beginning on or after 1 January 2023 and apply to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. Earlier application is permitted as long as this fact is disclosed.

The amendments are not expected to have a material impact on the Fund.

Disclosure of Accounting Policies – Amendments to IAS 1 and IFRS Practice Statement 2

In February 2021, the IASB issued amendments to IAS 1 and IFRS Practice Statement 2 Making Materiality Judgements, in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their ‘significant’ accounting policies with a requirement to disclose their ‘material’ accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

(a)(iii) Issued but not yet effective IFRSs (continued)

The amendments to IAS 1 are applicable for annual periods beginning on or after 1 January 2023 with earlier application permitted. Since the amendments to the Practice Statement 2 provide nonmandatory guidance on the application of the definition of material to accounting policy information, an effective date for these amendments is not necessary.

The Fund is currently assessing the impact of the amendments to determine the impact they will have on the Fund's accounting policy disclosures.

(b) Financial instruments

(i) **Classification**

In accordance with IFRS 9, the Sub-Funds classifies its financial assets and financial liabilities at initial recognition into the categories of financial assets and financial liabilities discussed below.

In applying that classification, a financial asset or financial liability is considered to be held for trading if:

- (a) It is acquired or incurred principally for the purpose of selling or repurchasing in the near term;
- (b) On initial recognition, it is part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent actual pattern of short-term profit-taking; or
- (c) It is a derivative (except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument).

Financial assets

The Sub-Funds classifies its financial assets as subsequently measured at amortised cost or measured at FVPL on the basis of both:

- The entity's business model for managing the financial assets; and
- The contractual cash flow characteristics of the financial assets

Financial assets measured at amortised cost

A debt instrument is measured at amortised cost if it is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest ("SPPI") on the principal amount outstanding. The Sub-Funds include in this category short-term non-financing receivables including interest receivable, interest receivable from swap contracts, other receivables, amounts due from broker, margin accounts and cash and cash equivalents.

Financial assets measured at FVPL

A financial asset is measured at FVPL if:

- (a) Its contractual terms do not give rise to cash flows on specified dates that are SPPI on the principal amount outstanding;
- (b) It is not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell; or

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

(b) Financial instruments (continued)

(i) **Classification (continued)**

- (c) At initial recognition, it is irrevocably designated as measured at FVPL when doing so eliminates or significantly reduces a measurement or recognition inconsistency that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases.

The Sub-Funds include in this category debt securities, investment funds and derivative contracts in an asset position held for trading.

Financial liabilities

Financial liabilities measured at amortised cost

This category includes all financial liabilities other than those measured at FVPL. The Sub-Funds includes in this category interest payable from swap contracts, amounts due to participating dealers, amounts due to broker, management fee payable, other payables and accruals, formation fee payable and cash collateral liabilities.

Financial liabilities measured at FVPL

This category includes derivative contracts in a liability position since they are classified as held for trading.

(ii) **Recognition**

The Sub-Funds recognise a financial asset or a financial liability when, and only when, it becomes a party to the contractual provisions of the instrument. Purchases and sales of financial assets at FVPL are accounted for on the trade date basis.

(iii) **Initial measurement**

Financial assets at FVPL are recorded in the statement of net assets at fair value. All transaction fees for such instruments are recognised directly in profit or loss.

Financial assets and liabilities (other than those classified as at FVPL) are measured initially at their fair value plus any directly attributable incremental costs of acquisition or issue.

(iv) **Subsequent measurement**

After initial measurement, the Sub-Funds measure financial instruments which are classified as at FVPL at fair value. Subsequent changes in the fair values of those financial instruments are recorded in "Net change in unrealised gain/loss on financial assets at FVPL". Interest earned on these instruments is recorded separately in "interest income" in the statement of profit or loss and other comprehensive income.

Financial assets, other than those classified as at FVPL, are measured at amortised cost using the effective interest method less any allowance for impairment. Gains and losses are recognised in profit or loss when the financial assets are derecognised or impaired, as well as through the amortisation process.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

(b) Financial instruments (continued)

(iv) *Subsequent measurement (continued)*

Financial liabilities, other than those classified as at FVPL, are measured at amortised cost using the effective interest method. Gains and losses are recognised in profit or loss when the liabilities are derecognised, as well as through the amortisation process.

The effective interest method is a method of calculating the amortised cost of a financial asset or a financial liability and of allocating the interest income or interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial asset or financial liability to the gross carrying amount of the financial asset or to the amortised cost of the financial liability. When calculating the effective interest rate, the Sub-Funds estimates cash flows considering all contractual terms of the financial instruments, but does not consider expected credit losses. The calculation includes all fees paid or received between parties to the contract that are an integral part of the effective interest rate, transaction fee and all other premiums or discounts.

(v) *Derecognition*

A financial asset is derecognised when the rights to receive cash flows from the financial asset have expired, or where the Sub-Funds have transferred its rights to receive cash flows from the financial asset, or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a pass-through arrangement and either the Sub-Funds have transferred substantially all the risks and rewards of the asset or the Sub-Funds have neither transferred nor retained substantially all the risks and rewards of the financial asset, but has transferred control of the asset.

When the Sub-Funds have transferred its rights to receive cash flows from an asset (or has entered into a pass-through arrangement), and has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the asset is recognised to the extent of the Sub-Funds' continuing involvement in the asset. In that case, the Sub-Funds also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Sub-Funds have retained. The Sub-Funds derecognise a financial liability when the obligation under the liability is discharged or cancelled, or expires.

Fair value measurement

The Sub-Funds measure its investments in financial instruments at fair value at the end of each reporting period.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- in the principal market for the asset or liability; or
- in the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Sub-Funds.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

The fair value for financial instruments that are listed or traded on an exchange is based on quoted last traded market prices, that are within the bid-ask spread.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

(b) Financial instruments (continued)

Fair value measurement (continued)

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Sub-Funds determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

Derivative financial instruments

Derivative financial instruments are recorded on a mark-to-market basis. Fair values are determined by using quoted market prices for futures contracts or calculated by reference to changes in specified prices of an underlying assets or otherwise a determined notional amount for swap agreements. All derivatives are carried as assets when amounts are receivable by the Sub-Funds and as liabilities when amounts are payable by the Sub-Funds.

Unrealised gains and losses arising from changes in fair value, and realised gains and losses are recognised in profit or loss.

(c) Revenue recognition

Interest income is recognised in profit or loss on a time-proportionate basis using the effective interest method.

Other income is recognised when it is probable that the economic benefits will flow to the Sub-funds and the other income can be reliably measured. Other income is recognised when the Sub-funds' right to receive payment has been established.

(d) Expenses

Expenses are recognised on an accrual basis.

(e) Cash and cash equivalents

Cash and cash equivalents in the statement of net assets comprise short-term deposits in banks which are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value, with original maturities of three months or less.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above, net of outstanding bank overdrafts when applicable.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

(f) Redeemable units

Redeemable units are classified as an equity instrument when:

- i. The redeemable units entitle the holder to a pro-rata share of the Sub-Funds' net assets in the event of the Sub-Funds' liquidation;
- ii. The redeemable units are in the class of instruments that is subordinate to all other classes of instruments;
- iii. All redeemable units in the class of instruments that is subordinate to all other classes of instruments have identical features;
- iv. The redeemable units do not include any contractual obligation to deliver cash or another financial asset other than the holder's rights to a pro-rata share of the Sub-Funds' net assets; or
- v. The total expected cash flows attributable to the redeemable units over the life of the instrument are based substantially on profit or loss, the change in the recognised net assets or the change in the fair value of the recognised and unrecognised net assets of the Sub-Funds over the life of the instrument.

In addition to the redeemable units having all the above features, the Sub-Funds must have no other financial instrument or contract that has:

- i. Total cash flows based substantially on profit or loss, the change in the recognised net assets or the change in the fair value of the recognised and unrecognised net assets of the Sub-Funds; and
- ii. The effect of substantially restricting or fixing the residual return to the redeemable unitholders.

The Sub-Funds' redeemable units meet the definition of puttable instruments classified as equity instruments under the revised IAS 32 and are classified as equity.

The Sub-Funds continuously assesses the classification of the redeemable units. If the redeemable units cease to have all the features or meet all the conditions set out to be classified as equity, the Sub-Funds will reclassify them as financial liabilities and measure them at fair value at the date of reclassification, with any differences from the previous carrying amount recognised in equity. If the redeemable units subsequently have all the features and meet the conditions to be classified as equity, the Sub-Funds will reclassify them as equity instruments and measure them at the carrying amount of the liabilities at the date of the reclassification.

The issuance, acquisition and cancellation of redeemable units are accounted for as equity transactions. Upon issuance of redeemable units, the consideration received is included in equity.

Transaction costs incurred by the Sub-Funds in issuing its own equity instruments are accounted for as a deduction from equity to the extent that they are incremental costs directly attributable to the equity transaction that otherwise would have been avoided.

The Sub-Funds' own equity instruments which are reacquired are deducted from equity and accounted for at amounts equal to the consideration paid, including any directly attributable incremental costs.

No gain or loss is recognised in profit or loss on the purchase, sale, issuance or cancellation of the Sub-Funds' own equity instruments.

Redeemable units can be redeemed in cash equal to a proportionate share of the Sub-Funds' net asset value. The Sub-Funds' net asset value per unit is calculated by dividing the net assets attributable to unitholders with the total number of outstanding units of the Sub-Funds.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

(g) Segmental reporting

Operating segments are reported in a manner consistent with the internal reporting used by the chief operating decision-maker. The Manager, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the chief operating decision-maker that makes strategic decisions.

(h) Margin accounts and amounts due to broker

Margin accounts represent cash deposits held with brokers as collateral against open futures contracts and maintained for Swap Counterparties as collateral against open Swap future contracts.

Amounts due to broker is a sum payable for securities purchased (in a regular way transaction) that have been contracted for, but not yet delivered, on the reporting date.

(i) Impairment of financial assets

For financial assets measured at amortised cost, impairment allowances are recognised under the general approach where expected credit losses are recognised in two stages. For credit exposures where there has not been a significant increase in credit risk since initial recognition, the Sub-Funds are required to provide for credit losses that result from possible default events within the next 12 months (stage 1). For those credit exposures where there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure irrespective of the timing of the default (stage 2).

The Sub-Funds consider a default has occurred when a financial asset is more than 90 days past due unless the Sub-Funds have reasonable and supportable information to demonstrate that a more appropriate default criterion should be applied.

(j) Net change in unrealised gains or losses on financial assets/liabilities at FVPL

This item includes changes in the fair value of financial assets/liabilities as at FVPL.

Unrealised gains and losses comprise changes in the fair value of financial instruments for the period and from reversal of prior period unrealised gains and losses for financial instruments which were realised in the reporting period.

(k) Net realised gains or losses on disposal of financial assets/liabilities at FVPL

Realised gains and losses on disposal of financial assets/financial liabilities classified as at FVPL are calculated using the first-in-first-out method for derivative financial instruments and weighted average method for investment funds.

(l) Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the statement of net assets if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the assets and settle the liabilities simultaneously.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

(m) Taxes

The Sub-funds are exempt from all forms of taxation in Hong Kong, including income, capital gains and withholding taxes. However, in some jurisdictions, investment income and capital gains are subject to withholding tax deducted from the source of the income. The Sub-Funds present the withholding tax separately from the gross investment income in profit or loss. For the purpose of the statement of cash flows, cash inflows from investments are presented net of withholding taxes, when applicable.

(n) Distributions to unitholders

Distributions are at the discretion of the Manager. A distribution to the Sub-Funds' unitholders is accounted for as a deduction from net assets attributable to unitholders. A proposed distribution is recognised as a liability in the period in which it is approved by the Manager. No distribution will be paid out of or effectively out of the Sub-Funds' capital.

(o) Formation fee

The formation fee is recognised as an expense in the period in which it is incurred.

(p) Transaction fees

Transaction fees are costs incurred to acquire financial assets/liabilities at FVPL. They include fees and commissions paid to agents, brokers and dealers. Transaction fees, when incurred, are immediately recognised in profit or loss as an expense.

(q) Related parties

A party is considered to be related to the Sub-Fund if:

- (a) the party is a person or a close member of that person's family and that person
 - (i) has control or joint control over the Sub-Fund;
 - (ii) has significant influence over the Sub-Fund; or
 - (iii) is a member of the key management personnel of the Sub-Fund or of a parent of the Sub-Fund;

or

- (b) the party is an entity where any of the following conditions applies:
 - (i) the entity and the Sub-Funds are members of the same group;
 - (ii) one entity is an associate or joint venture of the other entity (or of a parent, subsidiary or fellow subsidiary of the other entity);
 - (iii) the entity and the Sub-Funds are joint ventures of the same third party;
 - (iv) one entity is a joint venture of a third entity and the other entity is an associate of the third entity;
 - (v) the entity is a post-employment benefit plan for the benefit of employees of either the Sub-Funds or an entity related to the Sub-Funds;
 - (vi) the entity is controlled or jointly controlled by a person identified in (a);
 - (vii) a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and
 - (viii) the entity, or any member of a group of which it is a part, provides key management personnel services to the Sub-Funds or the parent of the Sub-Funds.

CSOP LEVERAGED AND INVERSE SERIES II

CONDENSED NOTES TO THE FINANCIAL STATEMENTS

30 June 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

(r) Foreign currency translations

Transactions during the period, including purchases and sales of securities, income and expenses, are translated at the rate of exchange prevailing on the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency rates of exchange ruling at the end of the reporting period. Differences arising on settlement or translation of monetary items are recognised in profit or loss.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined.

Foreign currency translation gains and losses on financial instruments classified as at FVPL are included in profit or loss.

CSOP LEVERAGED AND INVERSE SERIES II

INVESTMENT PORTFOLIO (Unaudited)

CSOP NASDAQ-100 Index Daily (2x) Leveraged Product

As at 30 June 2023

				Holdings Units	Fair value US\$	% of net assets
<u>Financial assets at fair value through profit or loss</u>						
<u>Listed investment funds</u>						
Hong Kong						
CSOP US Dollar Money Market ETF				7,000	750,571	5.03
CSOP US Dollar Money Market ETF- (Unlisted Share Class A)				852,578	914,219	6.13
					<u>1,664,790</u>	<u>11.16</u>
	Expiration date	Underlying assets	Counterparty	Contracts	Fair value US\$	% of net assets
<u>Futures contracts</u>						
The United States of America						
NASDAQ 100 E-MINI 15/09/2023	15 September 2023	NASDAQ 100 E-Mini Index	BNP PARIBAS MLA	97	655,765	4.39
					<u>655,765</u>	<u>4.39</u>
Total investments, at fair value					<u>2,320,555</u>	<u>15.55</u>
Total investments, at cost					<u>1,595,607</u>	

CSOP LEVERAGED AND INVERSE SERIES II

INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP Gold Futures Daily (2x) Leveraged Product

As at 30 June 2023

				Holdings Units	Fair value US\$	% of net assets
<u>Financial assets at fair value through profit or loss</u>						
<u>Listed investment funds</u>						
Hong Kong						
CSOP US Dollar Money Market ETF				288,795	30,965,871	18.22
<u>Unlisted investment funds</u>						
Singapore						
CSOP US Dollar Money Market ETF				1,132,692	1,172,948	0.69
					<u>32,138,819</u>	<u>18.91</u>
<u>Financial liabilities at fair value through profit or loss</u>						
	Expiration date	Underlying assets	Counterparty	Contracts	Fair value US\$	% of net assets
<u>Futures contracts</u>						
The United States of America						
GOLD 100 OZ FUTURE 29/08/2023	29 August 2023	Solactive Gold 1-Day Rolling Futures Index	Citigroup Global Markets Limited	900	(6,043,104)	(3.56)
GOLD 100 OZ FUTURE 29/08/2023	29 August 2023	Solactive Gold 1-Day Rolling Futures Index	BNP PARIBAS MLA	112	(345,180)	(0.20)
					<u>(6,388,284)</u>	<u>(3.76)</u>
	Position	Underlying assets	Counterparty	Contracts	Fair value US\$	% of net assets
<u>Swap future contracts</u>						
The United States of America						
GOLD 100 OZ FUTURE 29/08/2023	Long	Solactive Gold 1-Day Rolling Futures Index	Citigroup Global Markets Limited	750	(359,007)	(0.21)
					<u>(359,007)</u>	<u>(0.21)</u>
					<u>(6,747,291)</u>	<u>(3.97)</u>
Total investments, at fair value					<u>25,391,528</u>	<u>14.94</u>
Total investments, at cost					<u>30,906,583</u>	

CSOP LEVERAGED AND INVERSE SERIES II

INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP CSI 300 Index Daily (2x) Leveraged Product

As at 30 June 2023

					Holdings Units	Fair value RMB	% of net assets
<u>Financial assets at fair value through profit or loss</u>							
<u>Listed investment funds</u>							
Hong Kong							
CSOP RMB Money Market ETF					120,000	19,332,001	9.57
CSOP US Dollar Money Market ETF					18,000	14,008,951	6.93
						<u>33,340,952</u>	<u>16.50</u>
	Position	Underlying assets	Counterparty	Contracts		Fair value RMB	% of net assets
<u>Total return swaps contracts</u>							
China							
Total Return Swap (HSBC)	Long	CSI 300 Index	HSBC Hong Kong	5,500		180,125	0.09
Total Return Swap (CGML)	Long	CSI 300 Index	Citigroup Global Markets Limited	56,537		1,813,082	0.90
Total Return Swap (CICC)	Long	CSI 300 Index	Financial Trading Limited	43,516		1,410,611	0.70
						<u>3,403,818</u>	<u>1.69</u>
<u>Financial liabilities at fair value through profit or loss</u>							
	Expiration date	Position	Underlying assets	Counterparty	Notional amount	Fair value RMB	% of net assets
<u>Forward contracts</u>							
Hong Kong							
Buy Renminbi/Sell United States Dollars	31 July 2023	Long	Currency	Citibank, N.A., Hong Kong	98,649,590	(358,758)	(0.18)
						<u>(358,758)</u>	<u>(0.18)</u>
Total investments, at fair value						<u>36,386,012</u>	<u>18.01</u>
Total investments, at cost						<u>30,579,742</u>	

CSOP LEVERAGED AND INVERSE SERIES II

INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP CSI 300 Index Daily (-1x) Inverse Product

As at 30 June 2023

					Holdings Units	Fair value RMB	% of net assets
<u>Financial assets at fair value through profit or loss</u>							
<u>Listed investment funds</u>							
Hong Kong							
CSOP US Dollar Money Market ETF- (Unlisted Share Class A)					389,046	3,025,304	11.92
						<u>3,025,304</u>	<u>11.92</u>
<u>Financial liabilities at fair value through profit or loss</u>							
	Expiration date	Position	Underlying assets	Counterparty	Notional amount	Fair value RMB	% of net assets
<u>Forward contracts</u>							
Hong Kong							
Buy Renminbi/Sell United States Dollars	31 July 2023	Long	Currency	Citibank, N.A., Hong Kong	15,121,470	(54,992)	(0.22)
						<u>(54,992)</u>	<u>(0.22)</u>
		Position	Underlying assets	Counterparty	Contracts	Fair value RMB	% of net assets
<u>Total return swaps contracts</u>							
China							
Total Return Swap (HSBC)		Short	CSI 300 Index	HSBC Hong Kong CICC	(500)	(16,375)	(0.06)
Total Return Swap (CICC)		Short	CSI 300 Index	Financial Trading Limited	(2,602)	(85,225)	(0.34)
Total Return Swap (CGML)		Short	CSI 300 Index	Citigroup Global Markets Limited	(3,674)	(119,033)	(0.47)
						<u>(220,633)</u>	<u>(0.87)</u>
Total investments, at fair value						<u>2,749,679</u>	<u>10.83</u>
Total investments, at cost						<u>2,803,381</u>	

CSOP LEVERAGED AND INVERSE SERIES II

INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP FTSE China A50 Index Daily (2x) Leveraged Product

As at 30 June 2023

				Holdings Units	Fair value US\$	% of net assets
<u>Financial assets at fair value through profit or loss</u>						
<u>Listed investment funds</u>						
Hong Kong						
CSOP Hong Kong Dollar Money Market ETF				5,000	682,208	20.46
CSOP US Dollar Money Market ETF				5,000	536,500	16.09
					<u>1,218,708</u>	<u>36.55</u>
	Position	Underlying assets	Counterparty	Contracts	Fair value US\$	% of net assets
<u>Total return swaps contracts</u>						
China						
Total Return Swap (CGML)	Long	FTSE China A50 Index	Citigroup Global Markets Limited	278	49,478	1.48
Total Return Swap (SocGen)	Long	FTSE China A50 Index	Societe Generale	260	79,689	2.39
					<u>129,167</u>	<u>3.87</u>
Total investments, at fair value					<u>1,347,875</u>	<u>40.42</u>
Total investments, at cost					<u>1,180,031</u>	

CSOP LEVERAGED AND INVERSE SERIES II

INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP FTSE China A50 Index Daily (-1x) Inverse Product

As at 30 June 2023

				Holdings Units	Fair value US\$	% of net assets
<u>Financial assets at fair value through profit or loss</u>						
<u>Listed investment funds</u>						
Hong Kong						
CSOP Hong Kong Dollar Money Market ETF				4,000	545,767	19.55
CSOP US Dollar Money Market ETF				5,000	536,500	19.22
					<u>1,082,267</u>	<u>38.77</u>
<u>Financial liabilities at fair value through profit or loss</u>						
	Position	Underlying assets	Counterparty	Contracts	Fair value US\$	% of net assets
<u>Total return swaps contracts</u>						
China						
Total Return Swap (CGML)	Short	FTSE China A50 Index	Citigroup Global Markets Limited	(97)	(18,483)	(0.66)
Total Return Swap (SocGen)	Short	FTSE China A50 Index	Societe Generale	(128)	(39,231)	(1.41)
					<u>(57,714)</u>	<u>(2.07)</u>
Total investments, at fair value					<u>1,024,553</u>	<u>36.70</u>
Total investments, at cost					<u>1,046,660</u>	

CSOP LEVERAGED AND INVERSE SERIES II

INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP Gold Futures Daily (-1x) Inverse Product

As at 30 June 2023

				Holdings Units	Fair value US\$	% of net assets
<u>Financial assets at fair value through profit or loss</u>						
<u>Listed investment funds</u>						
Hong Kong						
CSOP US Dollar Money Market ETF- (Unlisted Share Class A)						
				117,488	125,983	17.95
					<u>125,983</u>	<u>17.95</u>
	Expiration date	Underlying assets	Counterparty	Contracts	Fair value US\$	% of net assets
<u>Futures contracts</u>						
The United States of America						
	29 August 2023	Solactive Gold 1-Day Rolling Futures Index	BNP Paribas MLA	(3)	21,260	3.03
					<u>21,260</u>	<u>3.03</u>
Total investments, at fair value					<u>147,243</u>	<u>20.98</u>
Total investments, at cost					<u>122,000</u>	

CSOP LEVERAGED AND INVERSE SERIES II

INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product

As at 30 June 2023

				Holdings Units	Fair value US\$	% of net assets
<u>Financial assets at fair value through profit or loss</u>						
<u>Listed investment funds</u>						
Hong Kong						
CSOP US Dollar Money Market ETF- (Unlisted Share Class A)						
				286,979	307,728	22.37
					<u>307,728</u>	<u>22.37</u>
<u>Financial liabilities at fair value through profit or loss</u>						
	Expiration date	Underlying assets	Counterparty	Contracts	Fair value US\$	% of net assets
<u>Futures contracts</u>						
The United States of America						
		Solactive WTI 1-Day Rolling Futures Index	BNP PARIBAS MLA			
WTI CRUDE FUTURE 20/07/2023	20 July 2023			(19)	(3,890)	(0.28)
					<u>(3,890)</u>	<u>(0.28)</u>
Total investments, at fair value					<u>303,838</u>	<u>22.09</u>
Total investments, at cost					<u>296,644</u>	

CSOP LEVERAGED AND INVERSE SERIES II

INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP CSI Brokerage Index Daily (2x) Leveraged Product

As at 30 June 2023

				Holdings Units	Fair value RMB	% of net assets
<u>Financial assets at fair value through profit or loss</u>						
<u>Listed investment funds</u>						
Hong Kong						
CSOP RMB Money Market ETF (Unlisted Share Class A)						
				116,503	1,254,006	24.13
					<u>1,254,006</u>	<u>24.13</u>
	Position	Underlying assets	Counterparty	Contracts	Fair value RMB	% of net assets
<u>Total return swaps contracts</u>						
China						
Total Return Swap (CICC)						
	Long	CSI 300 Index	CICC Financial Trading Limited	17,080	211,625	4.07
					<u>211,625</u>	<u>4.07</u>
Total investments, at fair value					<u>1,465,631</u>	<u>28.20</u>
Total investments, at cost					<u>1,251,313</u>	

CSOP LEVERAGED AND INVERSE SERIES II

STATEMENT OF MOVEMENTS IN INVESTMENT PORTFOLIO (Unaudited)

CSOP NASDAQ-100 Index Daily (2x) Leveraged Product

For the period ended 30 June 2023

	For the period from 1 January 2023 to 30 June 2023	For the period from 1 January 2022 to 30 June 2022
	% of net assets	% of net assets
<u>Financial assets at fair value through profit or loss</u>		
Listed investment funds		
Hong Kong	11.16	16.28
Futures contracts		
The United States of America	4.39	1.93
Total investments and derivative financial instruments	15.55	18.21
Other net assets	84.45	81.79
Total net assets	100.00	100.00

CSOP LEVERAGED AND INVERSE SERIES II

STATEMENT OF MOVEMENTS IN INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP Gold Futures Daily (2x) Leveraged Product

For the period ended 30 June 2023

	For the period from 1 January 2023 to 30 June 2023	For the period from 1 January 2022 to 30 June 2022
	% of net assets	% of net assets
<u>Financial assets at fair value through profit or loss</u>		
Listed investment funds		
Hong Kong	18.22	23.78
Unlisted investment funds		
Singapore	0.69	—
<u>Financial liabilities at fair value through profit or loss</u>		
Futures contracts		
The United States of America	(3.76)	(2.60)
Swap futures contracts		
The United States of America	(0.21)	(1.05)
Total investments and derivative financial instruments	14.94	20.13
Other net assets	85.06	79.87
Total net assets	100.00	100.00

CSOP LEVERAGED AND INVERSE SERIES II

STATEMENT OF MOVEMENTS IN INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP CSI 300 Index Daily (2x) Leveraged Product

For the period ended 30 June 2023

	For the period from 1 January 2023 to 30 June 2023	For the period from 1 January 2022 to 30 June 2022
	% of net assets	% of net assets
<u>Financial assets at fair value through profit or loss</u>		
Listed investment funds		
Hong Kong	16.50	21.45
Total return swap contracts		
China	1.69	1.77
<u>Financial liabilities at fair value through profit or loss</u>		
Forward contracts		
Hong Kong	(0.18)	(0.17)
Total investments and derivative financial instruments	18.01	23.05
Other net assets	81.99	76.95
Total net assets	100.00	100.00

CSOP LEVERAGED AND INVERSE SERIES II

STATEMENT OF MOVEMENTS IN INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP CSI 300 Index Daily (-1x) Inverse Product

For the period ended 30 June 2023

	For the period from 1 January 2023 to 30 June 2023	For the period from 1 January 2022 to 30 June 2022
	% of net assets	% of net assets
<u>Financial assets at fair value through profit or loss</u>		
Listed investment funds		
Hong Kong	11.92	52.57
<u>Financial liabilities at fair value through profit or loss</u>		
Total return swap contracts		
China	(0.87)	(0.93)
Forward contracts		
Hong Kong	(0.22)	(0.19)
Total investments and derivative financial instruments	10.83	51.45
Other net assets	89.17	48.55
Total net assets	100.00	100.00

CSOP LEVERAGED AND INVERSE SERIES II

STATEMENT OF MOVEMENTS IN INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP FTSE China A50 Index Daily (2x) Leveraged Product

For the period ended 30 June 2023

	For the period from 1 January 2023 to 30 June 2023	For the period from 1 January 2022 to 30 June 2022
	% of net assets	% of net assets
<u>Financial assets at fair value through profit or loss</u>		
Listed investment funds		
Hong Kong	36.55	38.96
Total return swap contracts		
China	3.87	4.61
Total investments and derivative financial instruments	40.42	43.57
Other net assets	59.58	56.43
Total net assets	100.00	100.00

CSOP LEVERAGED AND INVERSE SERIES II

STATEMENT OF MOVEMENTS IN INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP FTSE China A50 Index Daily (-1x) Inverse Product

For the period ended 30 June 2023

	For the period from 1 January 2023 to 30 June 2023	For the period from 1 January 2022 to 30 June 2022
	% of net assets	% of net assets
<u>Financial assets at fair value through profit or loss</u>		
Listed investment funds		
Hong Kong	38.77	51.17
<u>Financial liabilities at fair value through profit or loss</u>		
Total return swap contracts		
China	(2.07)	(2.00)
Total investments and derivative financial instruments	36.70	49.17
Other net assets	63.30	50.83
Total net assets	100.00	100.00

CSOP LEVERAGED AND INVERSE SERIES II

STATEMENT OF MOVEMENTS IN INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP Gold Futures Daily (-1x) Inverse Product

For the period ended 30 June 2023

	For the period from 1 January 2023 to 30 June 2023	Period from 19 October 2021 (date of inception) to 30 June 2022
	% of net assets	% of net assets
<u>Financial assets at fair value through profit or loss</u>		
Listed investment funds		
Hong Kong	17.95	21.17
Futures contracts		
The United States of America	3.03	2.24
Total investments and derivative financial instruments	20.98	23.41
Other net assets	79.02	76.59
Total net assets	100.00	100.00

CSOP LEVERAGED AND INVERSE SERIES II

STATEMENT OF MOVEMENTS IN INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product

For the period ended 30 June 2023

	For the period from 1 January 2023 to 30 June 2023	Period from 30 November 2021 (date of inception) to 30 June 2022
	% of net assets	% of net assets
<u>Financial assets at fair value through profit or loss</u>		
Listed investment funds		
Hong Kong	22.37	15.54
Futures contracts		
The United States of America	–	7.16
<u>Financial liabilities at fair value through profit or loss</u>		
Futures contracts		
The United States of America	(0.28)	–
Total investments and derivative financial instruments	22.09	22.70
Other net assets	77.91	77.30
Total net assets	100.00	100.00

CSOP LEVERAGED AND INVERSE SERIES II

STATEMENT OF MOVEMENTS IN INVESTMENT PORTFOLIO (Unaudited) (continued)

CSOP CSI Brokerage Index Daily (2x) Leveraged Product

For the period from 18 October 2022 (date of inception) to 30 June 2023

	Period from 18 October 2022 (date of inception) to 30 June 2023
	% of net assets
<hr/>	
<u>Financial assets at fair value through profit or loss</u>	
Listed investment funds	
Hong Kong	24.13
Total return swap contracts	
China	4.07
Total investments and derivative financial instruments	<hr/> 28.20
Other net assets	71.80
Total net assets	<hr/> <hr/> 100.00

CSOP LEVERAGED AND INVERSE SERIES II

HOLDINGS OF COLLATERAL (Unaudited)

CSOP CSI 300 Index Daily (2x) Leveraged Product

As at 30 June 2023

Collateral provider	Nature of the collateral	Credit rating	Rating agencies	Maturity tenor	Currency denomination	% of net asset value covered by collateral	Value of the collateral
						%	RMB
CICC Financial Trading Limited	Cash	N/A	N/A	N/A	CNH	0.79	1,600,000
							<u>1,600,000</u>

Custody/safe-keeping arrangement

Collateral provider	Amount of collateral received/held 30 June 2023	Proportion of collateral posted by the sub-fund 30 June 2023
	RMB	%
Custodians of collateral		
Pooled accounts		
Citibank, N.A, Hong Kong Branch	1,600,000	100.00

CSOP LEVERAGED AND INVERSE SERIES II

HOLDINGS OF COLLATERAL (Unaudited) (continued)

CSOP FTSE China A50 Index Daily (2x) Leveraged Product

As at 30 June 2023

Collateral provider	Nature of the collateral	Credit rating	Rating agencies	Maturity tenor	Currency denomination	% of net asset value covered by collateral	Value of the collateral
						%	US\$
Societe Generale	Cash	N/A	N/A	N/A	US\$	1.80	60,000
							<u>60,000</u>

Custody/safe-keeping arrangement

Collateral provider	Amount of collateral received/held 30 June 2023	Proportion of collateral posted by the sub-fund 30 June 2023
	US\$	%
Custodians of collateral		
Pooled accounts		
Citibank, N.A, Hong Kong Branch	60,000	100.00

CSOP LEVERAGED AND INVERSE SERIES II

PERFORMANCE RECORD (Unaudited)

Net asset value

	Dealing net asset value of the Sub-Fund*	Dealing net asset value per unit
At the end of financial period dated		
<u>CSOP NASDAQ-100 Index Daily (2x) Leveraged Product</u>		
30 June 2023	US\$14,943,397	US\$2.0697
31 December 2022	US\$9,195,141	US\$1.1465
31 December 2021	US\$2,342,980	US\$2.8573
31 December 2020	US\$3,086,281	US\$1.9051
<u>CSOP Gold Futures Daily (2x) Leveraged Product</u>		
30 June 2023	US\$169,991,323	US\$0.9561
31 December 2022	US\$193,672,596	US\$0.9127
31 December 2021	US\$234,232,737	US\$0.9984
31 December 2020	US\$271,187,100	US\$1.1328
<u>CSOP CSI 300 Index Daily (2x) Leveraged Product</u>		
30 June 2023	RMB202,704,314	RMB4.1200
31 December 2022	RMB203,327,583	RMB4.4984
31 December 2021	RMB270,294,903	RMB8.1414
<u>CSOP CSI 300 Index Daily (-1x) Inverse Product</u>		
30 June 2023	RMB26,063,463	RMB6.5159
31 December 2022	RMB26,521,666	RMB6.6304
31 December 2021	RMB156,724,855	RMB5.5973
<u>CSOP FTSE China A50 Index Daily (2x) Leveraged Product</u>		
30 June 2023	US\$3,357,368	US\$0.4418
31 December 2022	US\$3,254,388	US\$0.4786
31 December 2021	US\$7,152,083	US\$0.7152
<u>CSOP FTSE China A50 Index Daily (-1x) Inverse Product</u>		
30 June 2023	US\$2,813,800	US\$1.1724
31 December 2022	US\$2,793,927	US\$1.1641
31 December 2021	US\$22,941,808	US\$1.0621
<u>CSOP Gold Futures Daily (-1x) Inverse Product</u>		
30 June 2023	US\$729,964	US\$0.9125
31 December 2022	US\$2,266,562	US\$0.9444
<u>CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product</u>		
30 June 2023	US\$1,407,111	US\$0.5863
31 December 2022	US\$2,190,938	US\$0.5477
<u>CSOP CSI Brokerage Index Daily (2x) Leveraged Product</u>		
30 June 2023	RMB5,460,152	RMB6.8252

*The dealing net asset value of the Sub-Fund disclosed is calculated in accordance with the Trust's Prospectus.

CSOP LEVERAGED AND INVERSE SERIES II

PERFORMANCE RECORD (Unaudited) (continued)

Highest and lowest net asset value per unit

Financial period ended	Highest net asset value per unit	Lowest net asset value per unit
<u>CSOP NASDAQ-100 Index Daily (2x) Leveraged Product</u>		
30 June 2023	US\$2.0824	US\$1.1056
31 December 2022	US\$2.9130	US\$1.0963
31 December 2021	US\$2.9812	US\$1.7155
14 May 2020 (date of commencement of operations) to 31 December 2020	US\$1.9056	US\$0.9971
<u>CSOP Gold Futures Daily (2x) Leveraged Product</u>		
30 June 2023	US\$1.1094	US\$0.8862
31 December 2022	US\$1.2333	US\$0.7441
31 December 2021	US\$1.2035	US\$0.8759
4 June 2020 (date of commencement of operations) to 31 December 2021	US\$1.3874	US\$0.9527
<u>CSOP CSI 300 Index Daily (2x) Leveraged Product</u>		
30 June 2023	RMB5.2272	RMB4.0486
31 December 2022	RMB8.1407	RMB3.8067
24 July 2020 (date of commencement of operations) to 31 December 2021	RMB11.5661	RMB7.0000
<u>CSOP CSI 300 Index Daily (-1x) Inverse Product</u>		
30 June 2023	RMB6.6211	RMB6.0609
31 December 2022	RMB7.4369	RMB5.5967
24 July 2020 (date of commencement of operations) to 31 December 2021	RMB7.0000	RMB5.1118
<u>CSOP FTSE China A50 Index Daily (2x) Leveraged Product</u>		
30 June 2023	US\$0.5574	US\$0.4215
31 December 2022	US\$0.7151	US\$0.3611
19 January 2021 (date of commencement of operations) to 31 December 2021	US\$1.2386	US\$0.6419
<u>CSOP FTSE China A50 Index Daily (-1x) Inverse Product</u>		
30 June 2023	US\$1.2052	US\$1.0735
31 December 2022	US\$1.3629	US\$1.0471
19 January 2021 (date of commencement of operations) to 31 December 2021	US\$1.1510	US\$0.8901
<u>CSOP Gold Futures Daily (-1x) Inverse Product</u>		
30 June 2023	US\$0.9529	US\$0.8525
19 October 2021 (date of commencement of operations) to 31 December 2022	US\$1.0517	US\$0.8579
<u>CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product</u>		
30 June 2023	US\$0.6432	US\$0.5156
30 November 2021 (date of commencement of operations) to 31 December 2022	US\$1.0071	US\$0.4333

CSOP LEVERAGED AND INVERSE SERIES II

PERFORMANCE RECORD (Unaudited) (continued)

Highest and lowest net asset value per unit (continued)

Financial period ended	Highest net asset value per unit	Lowest net asset value per unit
<u>CSOP CSI Brokerage Index Daily (2x) Leveraged Product</u> 18 October 2022 (date of commencement of operations) to 30 June 2023	RMB9.0303	RMB6.2621

CSOP LEVERAGED AND INVERSE SERIES II

UNDERLYING INDEX CONSTITUENT STOCK DISCLOSURE (Unaudited)

The following are the securities which is a collective investment scheme authorised by the SFC that individually accounted for more than 10% but less than 30% of the net asset value of the Sub-Fund as at 30 June 2023.

As at 30 June 2023

CSOP NASDAQ-100 Index Daily (2x) Leveraged Product

There was no security (31 December 2022: Nil) which is a collective investment scheme authorised by the SFC that individually accounted for more than 10% but less than 30% of the net asset value of the Sub-Fund as at 30 June 2023.

During the period ended 30 June 2023, the NASDAQ-100 Index increased by 38.75% (31 December 2022: decreased by 32.97%) while the net asset value per unit of Sub-Fund increased by 80.84% (31 December 2022: decreased by 59.23%).

CSOP Gold Futures Daily (2x) Leveraged Product

There was one security (31 December 2022: One) which is a collective investment scheme authorised by the SFC that individually accounted for more than 10% but less than 30% of the net asset value of the Sub-Fund as at 30 June 2023.

	Fair Value US\$	% of assets
CSOP US Dollar Money Market ETF	30,965,871	18.22

During the period ended 30 June 2023, the Solactive Gold 1-Day Rolling Futures Index increased by 2.87% (31 December 2022: decreased by 2.73%) while the net asset value per unit of Sub-Fund increased by 4.76% (31 December 2022: decreased by 8.59%).

CSOP CSI 300 Index Daily (2x) Leveraged Product

There was no security (31 December 2022: Nil) which is a collective investment scheme authorised by the SFC that individually accounted for more than 10% but less than 30% of the net asset value of the Sub-Fund as at 30 June 2023.

During the period ended 30 June 2023, the CSI 300 Index decreased by 0.75% (31 December 2022: decreased by 21.63%) while the net asset value per unit of Sub-Fund decreased by 8.34% (31 December 2022: decreased by 44.74%).

CSOP CSI 300 Index Daily (-1x) Inverse Product

There was one security (31 December 2022: Nil) which is a collective investment scheme authorised by the SFC that individually accounted for more than 10% but less than 30% of the net asset value of the Sub-Fund as at 30 June 2023.

	Fair Value RMB	% of assets
CSOP US Dollar Money Market ETF- (Unlisted Share Class A)	3,025,304	11.92

During the period ended 30 June 2023, the CSI 300 Index decreased by 0.75% (31 December 2022: decreased by 21.63%) while the net asset value per unit of Sub-Fund decreased by 1.15% (31 December 2022: increased by 15.53%).

CSOP LEVERAGED AND INVERSE SERIES II

UNDERLYING INDEX CONSTITUENT STOCK DISCLOSURE (Unaudited) (continued)

CSOP FTSE China A50 Index Daily (2x) Leveraged Product

There were two securities (31 December 2022: Two) which is a collective investment scheme authorised by the SFC that individually accounted for more than 10% but less than 30% of the net asset value of the Sub-Fund as at 30 June 2023.

	Fair Value US\$	% of assets
CSOP Hong Kong Dollar Money Market ETF	682,208	20.46
CSOP US Dollar Money Market ETF	536,500	16.09

During the period ended 30 June 2023, the FTSE China A50 Index decreased by 3.96% (31 December 2022: decreased by 17.16%) while the net asset value per unit of Sub-Fund decreased by 7.54% (31 December 2022: decreased by 33.31%).

CSOP FTSE China A50 Index Daily (-1x) Inverse Product

There were two securities (31 December 2022: Two) which is a collective investment scheme authorised by the SFC that individually accounted for more than 10% but less than 30% of the net asset value of the Sub-Fund as at 30 June 2023.

	Fair Value US\$	% of assets
CSOP Hong Kong Dollar Money Market ETF	545,767	19.55
CSOP US Dollar Money Market ETF	536,500	19.22

During the period ended 30 June 2023, the FTSE China A50 Index decreased by 3.96% (31 December 2022: decreased by 17.16%) while the net asset value per unit of Sub-Fund increased by 0.88% (31 December 2022: increased by 8.71%).

CSOP Gold Futures Daily (-1x) Inverse Product

There was one security (31 December 2022: One) which is a collective investment scheme authorised by the SFC that individually accounted for more than 10% but less than 30% of the net asset value of the Sub-Fund as at 30 June 2023.

	Fair Value US\$	% of assets
CSOP US Dollar Money Market ETF- (Unlisted Share Class A)	125,983	17.95

During the period ended 30 June 2023, the Solactive Gold 1-Day Rolling Futures Index increased by 2.87% (from 19 October 2021 (date of inception) to 31 December 2022: increased by 0.31%) while the net asset value per unit of Sub-Fund decreased by 5.77% (from 19 October 2021 (date of inception) to 31 December 2022: decreased by 6.90%).

CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product

There was one security (31 December 2022: One) which is a collective investment scheme authorised by the SFC that individually accounted for more than 10% but less than 30% of the net asset value of the Sub-Fund as at 30 June 2023.

	Fair Value US\$	% of assets
CSOP US Dollar Money Market ETF- (Unlisted Share Class A)	307,728	22.37

During the period ended 30 June 2023, the Solactive WTI 1-Day Rolling Futures Index decreased by 12.84% (from 30 November 2021 (date of inception) to 31 December 2022: increased by 42.95%) while the net asset value per unit of Sub-Fund increased by 6.40% (from 30 November 2021 (date of inception) to 31 December 2022: decreased by 46.12%).

CSOP LEVERAGED AND INVERSE SERIES II

UNDERLYING INDEX CONSTITUENT STOCK DISCLOSURE (Unaudited) (continued)

CSOP CSI Brokerage Index Daily (2x) Leveraged Product

There was one security which is a collective investment scheme authorised by the SFC that individually accounted for more than 10% but less than 30% of the net asset value of the Sub-Fund as at 30 June 2023.

	Fair Value <i>RMB</i>	% of assets
CSOP RMB Money Market ETF (Unlisted Share Class A)	1,254,006	24.13

During the period from 18 October 2022 (date of inception) to 30 June 2023, the CSI All Share Investment Banking & Brokerage Index increased by 3.60% while the net asset value per unit of Sub-Fund decreased by 7.00%.

CSOP LEVERAGED AND INVERSE SERIES II

DETAILS IN RESPECT OF SWAP FEES FOR FINANCIAL DERIVATIVE INSTRUMENTS (Unaudited)

The Sub-Funds will bear the swap fees, which are subject to the discussion and consensus between the Manager and the Swap Counterparty based on the actual market circumstances on a case-by-case basis.

CSOP Gold Futures Daily (2x) Leveraged Product

The swap fees of the Sub-Fund were USD Nil for the period ended 30 June 2023 (for the period ended 30 June 2022: USD Nil).

CSOP CSI 300 Index Daily (2x) Leveraged Product

The swap fees of the Sub-Fund were RMB11,588,689* for the period ended 30 June 2023 (for the period ended 30 June 2022: RMB5,179,895*).

CSOP CSI 300 Index Daily (-1x) Inverse Product

The swap fees of the Sub-Fund were RMB33,101* for the period ended 30 June 2023 (for the period ended 30 June 2022: RMB1,917,586*).

CSOP FTSE China A50 Index Daily (2x) Leveraged Product

The swap fees of the Sub-Fund were USD Nil for the period ended 30 June 2023 (for the period ended 30 Jun 2022: USD Nil).

CSOP FTSE China A50 Index Daily (-1x) Inverse Product

The swap fees of the Sub-Fund were USD Nil for the period ended 30 June 2023 (for the period ended 30 June 2022: USD Nil).

CSOP Gold Futures Daily (-1x) Inverse Product

The swap fees of the Sub-Fund were USD Nil for the period ended 30 June 2023 (for the period from 19 October 2021 (date of inception) to 30 June 2022: USD Nil).

CSOP WTI Crude Oil Futures Daily (-1x) Inverse Product

The swap fees of the Sub-Fund were USD Nil for the period ended 30 June 2023 (for the period from 30 November 2021 (date of inception) to 30 June 2022: USD Nil).

CSOP CSI Brokerage Index Daily (2x) Leveraged Product

The swap fees of the Sub-Fund were RMB788,651* for the period from 18 October 2022 (date of inception) to 30 June 2023.

*A positive figure denotes the fee that the Sub-Fund pays to the swap counterparties. A negative figure denotes the fee that the swap counterparties pay to the Sub-Fund.

CSOP LEVERAGED AND INVERSE SERIES II

MANAGEMENT AND ADMINISTRATION

Manager

CSOP Asset Management Limited
2801-2803 & 3303-3304
Two Exchange Square
8 Connaught Place
Central
Hong Kong

Directors of the Manager

Chen Ding
Gaobo Zhang
Xiaosong Yang
Xiuyan Liu (resigned on 17 June 2022)
Yi Zhou
Yundong Zhu (appointed on 17 June 2022)
Zhiwei Liu
Zhongping Cai

Registrar

Computershare Hong Kong Investor Services Limited
46/F, Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

Legal Counsel to the Manager

Simmons & Simmons
30/F, One Taikoo Place
979 King's Road
Hong Kong

Auditor

Ernst & Young
27/F, One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

Administrator and Custodian

Citibank, N.A, Hong Kong Branch
50/F., Champion Tower
Three Garden Road
Central
Hong Kong

Trustee

Cititrust Limited
50/F., Champion Tower
Three Garden Road
Central
Hong Kong

Service Agent

HK Conversion Agency Services Limited
1/F, One & Two Exchange Square
8 Connaught Place
Central
Hong Kong

Listing Agent

Altus Capital Limited
21 Wing Wo Street
Central
Hong Kong



www.csopasset.com

Telephone: (852) 3406 5688

2801-2803, Two Exchange Square, 8 Connaught Place, Central, Hong Kong